Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Board's Compensation Committee granted restricted stock unit awards for 951 shares of common stock to five new non-executive employees on July 1, 2026. These inducement grants were made under the company's 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The awards will vest in four equal annual installments, contingent upon continued employment.
Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor
Praxis Precision Medicines, Inc. announced that its Audit Committee dismissed Ernst & Young LLP (EY) and engaged KPMG LLP as its independent registered public accounting firm, effective June 29, 2026. The company stated that there were no disagreements with EY on accounting principles, financial disclosures, or audit procedures for the 2024 and 2025 fiscal years, and EY's reports for those years contained no adverse opinions. Praxis also confirmed that it did not consult KPMG on any accounting or auditing matters prior to their appointment.
Praxis uses inducement plan to grant 951 shares to five hires
Praxis Precision Medicines, Inc. announced the grant of 951 restricted stock units (RSUs) to five new non-executive employees under its 2024 Inducement Plan. These RSUs, designed to attract and retain talent, will vest in four equal annual installments, in accordance with Nasdaq Listing Rule 5635(c)(4). The company is a biopharmaceutical firm focused on CNS precision neuroscience and develops therapies for disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 951 shares of common stock to five new non-executive employees. These grants were made under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), as an inducement for their employment. The awards will vest in four equal annual installments, contingent upon continued employment.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that on July 1, 2026, its Compensation Committee granted restricted stock unit awards covering 951 shares of common stock to five new non-executive employees. These grants were made under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), as an inducement for their employment. The restricted stock units will vest in four equal annual installments, contingent upon continued employment.
Price to sales forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX
This article provides access to the "Price to sales forward" financial data for Praxis Precision Medicines, Inc. (NASDAQ: PRAX) on TradingView. It highlights the company's financial overview within the pharmaceuticals sector and indicates that the market is currently closed with no trades. The content primarily serves as a gateway to financial metrics for the specified company.
Price to book forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX
This article provides financial information for Praxis Precision Medicines, Inc. (NASDAQ: PRAX), specifically focusing on its Price to Book Forward metric. It indicates that the company's financial data is provided by reputable sources like ICE Data Services and FactSet. The content suggests that this is a detailed financial overview for investors and analysts interested in PRAX.
Price to earnings forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX
This article focuses on the "Price to earnings forward" metric for Praxis Precision Medicines, Inc. (NASDAQ: PRAX). It appears to be a financial data page from TradingView, indicating that the market for PRAX was closed with no trades at the time of viewing.
Praxis Precision Medicines stock falls on FDA review delay
Praxis Precision Medicines (NASDAQ:PRAX) shares fell 7% after the FDA extended its review period for relutrigine by three months. The new PDUFA target action date is December 27, 2026, due to the company submitting additional sensitivity analyses of existing clinical data. Relutrigine is being reviewed for SCN2A and SCN8A developmental and epileptic encephalopathies, and the FDA did not request new studies or cite safety concerns.
Praxis Precision Medicines Announces Extension Period for
Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine by three months, setting an updated PDUFA date of December 27, 2026. This extension allows for additional time to review new sensitivity analyses of existing clinical data submitted by Praxis. The company remains confident in the application's strength and continues to collaborate with the FDA, emphasizing that no new studies were requested and no safety or manufacturing concerns were cited.
Praxis Precision Medicines stock falls on FDA review delay
Praxis Precision Medicines (NASDAQ:PRAX) shares declined 7% after the FDA extended the review period for its New Drug Application for relutrigine by three months, setting a new PDUFA target action date of December 27, 2026. The delay is due to the company's submission of additional sensitivity analyses, which the FDA classified as a "major amendment," though no new studies or safety concerns were cited. Relutrigine is intended for SCN2A and SCN8A developmental and epileptic encephalopathies, conditions for which there are currently no FDA-approved treatments.
FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026
The FDA has extended the review period for Praxis Precision Medicines' New Drug Application (NDA) for relutrigine by three months, moving the PDUFA target action date to December 27, 2026. This extension occurred because Praxis submitted additional sensitivity analyses of existing clinical data, which the FDA classified as a "major amendment." The FDA did not request new clinical studies or raise any safety or manufacturing concerns, and Praxis remains confident in its application for treating SCN2A and SCN8A developmental and epileptic encephalopathies.
FDA delays Praxis relutrigine review by three months to Dec. 27
Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine by three months, shifting the PDUFA target action date from September 27, 2026, to December 27, 2026. This extension is due to a "major amendment" submission of additional sensitivity analyses of existing clinical data by Praxis, rather than any new safety or manufacturing concerns or requests for new clinical studies. Despite a moderate negative market reaction to the news, Praxis remains confident in the relutrigine application for patients with SCN2A and SCN8A developmental and epileptic encephalopathies.
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Growth Benchmark Index
Praxis Precision Medicines, Inc., trading under the NasdaqGS:PRAX symbol, has been removed from the Russell Microcap Growth Benchmark Index. This news was published on June 29, 2026, at 08:13 am EDT. The company specializes in central nervous system precision neuroscience biopharmaceuticals, focusing on therapies for CNS disorders.
Praxis gains FDA breakthrough therapy status for elsunersen for encephalopathy
Praxis Precision Medicines announced that the FDA has granted Breakthrough Therapy Designation to elsunersen for the treatment of pediatric patients with early-onset severe epileptic encephalopathy caused by KCNQ2 gain-of-function variants. This designation was based on positive data from a Phase 2/3 study, which showed significant reductions in seizure frequency and improvements in developmental milestones, underscoring the potential of elsunersen to address a critical unmet medical need.
Praxis Precision Medicines director Jill DeSimone sells $3.6m in shares
Jill DeSimone, a director at Praxis Precision Medicines, Inc. (NASDAQ:PRAX), sold approximately $3.61 million worth of common stock after exercising stock options. The transactions, executed under a Rule 10b5-1 trading plan, occurred at prices ranging from $301.44 to $315.705 per share. Despite the sale, Praxis recently received Breakthrough Therapy Designation for elsunersen and held its 2026 Annual Meeting, though Truist Securities lowered its price target due to a Phase 3 trial failure for vormatrigine.
Praxis Precision Medicines(PRAX.US) Director Sells US$3.61 Million in Common Stock
A director at Praxis Precision Medicines (PRAX.US), DeSimone Jill, sold 11,600 shares of common stock on June 24, 2026. The sale was valued at $3.61 million, with shares trading at an average price of $311.322. This transaction is considered an insider sale per federal securities laws, which require directors and other insiders to report their securities transactions.
Praxis (PRAX) director logs 11,600-share sale after option exercises
Jill DeSimone, a director at Praxis Precision Medicines (PRAX), exercised options for 11,600 shares and subsequently sold all 11,600 shares in open-market transactions on June 24, 2026. These sales, conducted under a Rule 10b5-1 trading plan, occurred at weighted-average prices in the low $300s. Following these transactions, DeSimone directly holds 10,903 Praxis common shares.
Praxis Precision Medicines director Jill DeSimone sells $3.6m in shares
Jill DeSimone, a director at Praxis Precision Medicines (NASDAQ:PRAX), sold approximately $3.61 million worth of common stock on June 24, 2026, after exercising stock options. The sales were executed under a Rule 10b5-1 trading plan, and followed the stock's significant 644% return over the past year, though InvestingPro analysis suggests the stock is currently overvalued. This transaction comes amidst recent company developments including a Breakthrough Therapy Designation for its drug elsunersen and a lowered price target by Truist Securities after a Phase 3 trial failure.
Praxis Precision Medicines, Inc. Actuals & Estimates (BOATS:PRAX)
This article provides actuals and estimates for Praxis Precision Medicines, Inc. (PRAX) traded on the BOATS exchange. It covers financial data, analyst forecasts with price targets ranging from $162.00 to $1,201.00, past stock performance including all-time high and low, and information on upcoming earnings reports. Additionally, it details recent earnings per share and revenue figures, net income, employee count, and confirms that the company does not pay dividends.
Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree
Praxis Precision Medicines (PRAX) stock has experienced a 27% surge over a 6-day winning streak, increasing its market cap by $2.0 billion to $9.5 billion. The article highlights the importance of predictive signals over notifications for investors and presents a detailed comparison of PRAX's returns against the S&P 500 across various periods. It also provides key financial data for the company.
Form 144 Praxis Precision Medicines For: 24 June By Investing.com
This article from Investing.com announces the filing of Form 144 for Praxis Precision Medicines on June 24. It mentions the stock symbol PRAX and points to the news being relevant for stock market investors. The content itself is very short, primarily serving as an announcement within a larger financial news platform.
Praxis Precision Medicines, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Praxis Precision Medicines, Inc. (PRAX). The filing indicates a proposed sale of 11,600 shares of common stock with an aggregate market value of $3,611,336.04, acquired through a stock option exercise on June 24, 2026, and to be sold on NASDAQ. The filing has a neutral impact and sentiment according to StockTitan.
Praxis Precision Medicines (PRAX): Best Upside Stocks to Buy According to Hedge Funds
Praxis Precision Medicines Inc. (NASDAQ: PRAX) has been identified by hedge funds as a top upside stock, particularly after receiving FDA Breakthrough Therapy Designation for elsunersen, its experimental SCN2A-DEE seizure treatment. This designation, based on strong EMBRAVE Part A trial results, paves the way for an expedited regulatory review and marks the third such designation for Praxis's late-stage pipeline. The company is a clinical-stage biopharmaceutical firm focusing on CNS disorders and is recognized for its Solidus ASO platform.
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
Praxis Precision Medicines received Breakthrough Therapy Designation from the FDA for elsunersen (PRAX-222), its investigational therapy for SCN2A-DEE, a rare genetic epilepsy. This designation, the company's third, is expected to accelerate the development and regulatory review process. The decision was based on positive Phase 1/2 trial results showing a significant reduction in seizures and improvements in other clinical measures for pediatric patients.
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Praxis Precision Medicines announced that the FDA has granted Breakthrough Therapy Designation (BTD) for elsunersen (PRAX-222) to treat seizures associated with SCN2A-DEE caused by gain-of-function variants. This designation is based on positive results from the EMBRAVE Part A trial, which showed a 77% sham-adjusted reduction in monthly seizures that was sustained for up to one year. The BTD will expedite the development and regulatory review of elsunersen, which could become the first disease-modifying, targeted therapy for this rare genetic epilepsy.
FDA Breakthrough Therapy nod for Praxis (PRAX) seizure drug elsunersen
Praxis Precision Medicines (PRAX) has received FDA Breakthrough Therapy Designation for its seizure drug elsunersen (PRAX-222). This designation aims to expedite the development and regulatory review process for treatments of serious conditions, supported by positive early clinical data from the EMBRAVE Part A trial in pediatric patients with SCN2A-DEE. The status indicates preliminary evidence of substantial improvement over existing therapies for seizures associated with SCN2A developmental and epileptic encephalopathy.
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Praxis Precision Medicines has received Breakthrough Therapy Designation (BTD) from the FDA for elsunersen (PRAX-222) to treat seizures linked to SCN2A Developmental and Epileptic Encephalopathy (SCN2A-DEE) caused by gain-of-function variants. This designation is supported by positive results from the EMBRAVE Part A trial, which showed a 77% sham-adjusted reduction in monthly seizures. Elsunersen is described as a potential first disease-modifying, targeted therapy for this condition, with the company progressing rapidly through a streamlined single-arm registrational pathway.
FDA gives Praxis seizure drug Breakthrough Therapy status
Praxis Precision Medicines has received FDA Breakthrough Therapy Designation for its drug elsunersen (PRAX-222) to treat seizures associated with SCN2A Developmental and Epileptic Encephalopathy (SCN2A-DEE). This designation, based on strong clinical trial results showing a significant reduction in seizures and sustained benefits, aims to expedite the drug's development and regulatory review process. The company is currently enrolling patients for its pivotal EMBRAVE3 registrational study, which utilizes a streamlined single-arm design aligned with the FDA.
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Praxis Precision Medicines announced that the FDA has granted Breakthrough Therapy Designation (BTD) for elsunersen (PRAX-222) for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (SCN2A-DEE) caused by Gain of Function variants. This designation was based on positive results from the EMBRAVE Part A trial, which showed a 77% sham-adjusted reduction in monthly seizures, with sustained benefit for up to one year. The pivotal EMBRAVE3 study is now enrolling under a streamlined, single-arm pathway, aiming to bring this potentially disease-modifying therapy to patients quickly.
Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation
Praxis Precision Medicines' shares rose 4% after the FDA granted Breakthrough Therapy Designation to elsunersen for SCN2A Developmental and Epileptic Encephalopathy (SCN2A-DEE). This designation follows positive results from the EMBRAVE study, showing a 77% reduction in monthly seizure frequency. The company is currently enrolling patients for its pivotal EMBRAVE3 trial for this rare and severe genetic epilepsy.
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Praxis Precision Medicines announced that the FDA granted Breakthrough Therapy Designation (BTD) for elsunersen (PRAX-222) for treating seizures linked to SCN2A-DEE caused by Gain of Function variants. This designation, supported by positive results from the EMBRAVE Part A trial showing a 77% reduction in seizures, aims to expedite development and regulatory review. Elsunersen also holds Orphan Drug and Rare Pediatric Disease designations from the FDA, and Orphan Drug and PRIME designations from the EMA, positioning it as a potential first disease-modifying therapy for this rare genetic epilepsy.
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Praxis Precision Medicines has received FDA Breakthrough Therapy Designation for elsunersen (PRAX-222) to treat seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variants. This designation was based on positive results from the EMBRAVE Part A trial, which showed a 77% sham-adjusted reduction in monthly seizures. The company is now pursuing a streamlined, single-arm registrational pathway for its pivotal EMBRAVE3 study, aiming to bring this potential disease-modifying therapy to patients quickly.
Praxis Precision Medicines (PRAX) Q4 2025 earnings summary
Praxis Precision Medicines (PRAX) achieved significant clinical and regulatory milestones in 2025, including positive readouts for several drug candidates and the submission of two New Drug Applications. The company is transitioning to a commercial-stage entity with a combined revenue potential exceeding $20 billion for its four late-stage assets. Despite an increase in operating expenses, Praxis ended 2025 with $926M in cash and investments, projected to fund operations into 2028 after a January 2026 public offering.
Praxis Precision Medicines’ Rising Institutional Backing (PRAX) Is Shaping Its Late-Stage Epilepsy Story
Institutional ownership in Praxis Precision Medicines (PRAX) has significantly increased, placing it at the top of its biotech peer group for concentration of institutional shareholding. This surge highlights professional investor interest in Praxis's late-stage epilepsy and movement disorder programs, especially with the recent priority FDA review for relutrigine, despite past setbacks. The article suggests this strong institutional backing could influence the company's investment narrative, providing a balance to the risks associated with single trial outcomes.
Praxis Precision Medicines (PRAX) Proxy filing Summary
This article summarizes Praxis Precision Medicines' (PRAX) proxy filing for its 2026 Annual Meeting. Key voting matters include the election of three Class III directors, ratification of Ernst & Young LLP as auditor, and an advisory vote on executive compensation. The summary also highlights the company's significant achievements in 2025, including positive trial results, FDA designations, and a substantial increase in stock price, along with recent investor events and financial updates.
Praxis Precision Medicines (PRAX) Q1 2026 earnings summary
Praxis Precision Medicines (PRAX) reported a Q1 2026 net loss of $92.6 million, with operating expenses reaching $105.9 million. Despite the loss, the company's cash reserves grew to $1.4 billion, largely due to a public offering, which is expected to fund operations into 2028. Praxis is advancing four late-stage CNS assets, with FDA decisions for ulixacaltamide and relutrigine expected in 2027, and several key topline clinical trial results anticipated throughout 2026 and 2027.
Precision Trading with Praxis Precision Medicines Inc. (PRAX) Risk Zones
This article analyzes Praxis Precision Medicines Inc. (PRAX) using AI models to provide precision trading risk zones and strategies. It identifies a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. Three distinct trading strategies — Position, Momentum Breakout, and Risk Hedging — are outlined with specific entry, target, and stop-loss levels.
Precision Trading with Praxis Precision Medicines Inc. (PRAX) Risk Zones
This article provides "precision trading" insights for Praxis Precision Medicines Inc. (NASDAQ: PRAX), detailing AI-generated signals for different trading strategies. It outlines entry, target, and stop-loss zones for long, breakout, and short positions, along with multi-timeframe signal analysis indicating varying strengths of support and resistance. The analysis points to positive near-term sentiment but a weak mid-term bias within a long-term strength context, noting elevated downside risk due to a lack of additional long-term support signals.
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200
Piper Sandler has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US) and maintained its target price at $1,200. This continued endorsement suggests confidence in the company's future performance.
Praxis a new outperform at RBC on recent pullback
RBC Capital Markets has initiated coverage on Praxis Precision Medicines (PRAX) with an "outperform" rating, citing a recent stock pullback as an opportune entry point. The firm anticipates the next six months to be transformative for the company and has set a price target of $449, suggesting a potential upside of approximately 66% from the June 17 close.
Praxis Precision Medicines Inc (PRAX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for Praxis Precision Medicines Inc (PRAX). It notes that PRAX has distributed no dividends over the past five years and details multiple 15-to-1 merger-related stock splits that occurred on November 22, 2023. The stock closed at $269.88 on June 17, 2024, with a market cap of $7.53 billion.
Praxis Precision Medicines Inc (PRAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides an overview of Praxis Precision Medicines Inc (PRAX) stock information, including its market capitalization, recent stock performance, and a note on the unavailability of its revenue breakdown by business segment and region. The company's financials, discussions, analysis, and shareholder information are also mentioned as available categories on the platform. The platform states that relevant revenue data has not yet been disclosed by the company.
Praxis Precision Medicines Inc (PRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Praxis Precision Medicines Inc (PRAX) has an earnings forecast score of 8.35, placing it 134th in the Biotechnology & Medical Research industry. Analysts have an average price target of $340.00, with a consensus "Buy" rating based on 17 analysts. The company's previous quarter EPS was -$3.49 against an expectation of -$3.20, and the next quarter's EPS is projected to be -$3.65.
Praxis Precision Medicines Inc (PRAX) Institutional Confidence
Praxis Precision Medicines Inc (PRAX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 24.71% quarter-over-quarter to 114.11%, with Steven Cohen being the largest institutional shareholder. Major institutional investors like Janus Henderson Investors and Perceptive Advisors LLC have significantly increased their holdings.
Praxis (PRAX) director awarded 1,371 RSUs and 648-share stock option
Praxis Precision Medicines director Merit Ester Cudkowicz was granted 1,371 restricted stock units (RSUs) and an option to purchase 648 shares. The RSUs vest in a single installment by June 10, 2027, or the 2027 annual meeting, while the stock option vests in 12 equal monthly installments starting July 10, 2026, with an exercise price of $240.66 per share. Following these grants, Dr. Cudkowicz directly holds 1,371 common shares and 648 options.
Praxis Precision Medicines (PRAX) shareholders approve board, auditor and say-on-pay
Praxis Precision Medicines, Inc. (PRAX) held its 2026 Annual Meeting of Stockholders on June 10, 2026, where shareholders elected three Class III directors, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and approved the compensation of named executive officers on an advisory basis. All proposals received majority support, as detailed in the company's 8-K filing.
Praxis (PRAX) director Kindler awarded RSUs and stock options as compensation
Jeffrey B. Kindler, a director at Praxis Precision Medicines (PRAX), received equity awards including 1,371 restricted stock units (RSUs) and stock options for 648 shares at an exercise price of $240.66. These grants are part of his routine director compensation, vesting over time, and do not represent open-market transactions. Following the RSU grant, Kindler's common stock holdings now total 2,537 shares.
Praxis (PRAX) director Jill DeSimone granted 1,371 RSUs and 648 options
Praxis Precision Medicines director Jill DeSimone was granted 1,371 restricted stock units (RSUs) and 648 stock options as part of her compensation. The RSUs vest in a single installment by June 10, 2027, or the company's 2027 annual meeting, while the stock options, priced at $240.66 per share, vest in twelve equal monthly installments starting July 10, 2026. After these grants, DeSimone directly holds 2,337 shares of common stock and 648 stock options.
Praxis Precision Medicines (PRAX) director granted RSUs and options as equity pay
Praxis Precision Medicines director Jeffrey Chodakewitz received equity compensation in the form of 1,371 restricted stock units (RSUs) and options for 648 shares. The RSUs will vest in a single installment by June 10, 2027, or the company's 2027 annual meeting, while the stock options, with an exercise price of $240.66, will vest in monthly installments starting July 10, 2026, and expire on June 10, 2036. These awards are part of his compensation and are not open-market purchases.
